(Q34667362)

3 August 2017

Progressive paresthesias after cessation of therapy with very high-dose cisplatin (English)

1 reference

3 August 2017

1 reference

4

1 reference

3 August 2017

S M Grunberg

1

1 reference

3 August 2017

S Sonka

series ordinal

2

1 reference

3 August 2017

L L Stevenson

series ordinal

3

1 reference

3 August 2017

1 January 1989

1 reference

Cancer Chemotherapy and Pharmacology

3 August 2017

1 reference

3 August 2017

25

1 reference

3 August 2017

1

1 reference

3 August 2017

62-64

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00694340

3 August 2017

0 references

cites work

Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer.

1 reference

12 December 2020

High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer

1 reference

12 December 2020

Toxic effects of cis-dichlorodiammineplatinum(II) in man.

1 reference

12 December 2020

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

1 reference

12 December 2020

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1 reference

12 December 2020

Carboplatin: the clinical spectrum to date

1 reference

12 December 2020

Evolution of high-dose cisplatin

1 reference

12 December 2020

Unusual presentation of cis-platinum neuropathy

1 reference

12 December 2020

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

1 reference

12 December 2020

High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00694340

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference